ATE238052T1 - Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels - Google Patents
Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegelsInfo
- Publication number
- ATE238052T1 ATE238052T1 AT98938151T AT98938151T ATE238052T1 AT E238052 T1 ATE238052 T1 AT E238052T1 AT 98938151 T AT98938151 T AT 98938151T AT 98938151 T AT98938151 T AT 98938151T AT E238052 T1 ATE238052 T1 AT E238052T1
- Authority
- AT
- Austria
- Prior art keywords
- hydroxamic acids
- substituted alkane
- alpha levels
- reducing tnf
- levels
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
- C07D209/66—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with oxygen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90397597A | 1997-07-31 | 1997-07-31 | |
PCT/US1998/015868 WO1999006041A1 (en) | 1997-07-31 | 1998-07-30 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE238052T1 true ATE238052T1 (de) | 2003-05-15 |
Family
ID=25418328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98938151T ATE238052T1 (de) | 1997-07-31 | 1998-07-30 | Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels |
Country Status (20)
Country | Link |
---|---|
US (3) | US6214857B1 (de) |
EP (1) | EP1035848B1 (de) |
JP (1) | JP2001511448A (de) |
KR (1) | KR100716475B1 (de) |
CN (1) | CN1265590A (de) |
AT (1) | ATE238052T1 (de) |
AU (1) | AU737008B2 (de) |
BR (1) | BR9815895A (de) |
CA (1) | CA2295295A1 (de) |
CZ (1) | CZ299873B6 (de) |
DE (1) | DE69813876T2 (de) |
ES (1) | ES2196592T3 (de) |
FI (1) | FI119841B (de) |
HU (1) | HUP0003761A3 (de) |
NO (1) | NO315043B1 (de) |
NZ (1) | NZ502379A (de) |
PT (1) | PT1035848E (de) |
RU (1) | RU2199530C2 (de) |
TR (1) | TR200000221T2 (de) |
WO (1) | WO1999006041A1 (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
US5929117A (en) * | 1996-08-12 | 1999-07-27 | Celgene Corporation | Immunotherapeutic agents |
RU2199530C2 (ru) * | 1997-07-31 | 2003-02-27 | Селджин Корпорейшн | ЗАМЕЩЕННЫЕ ГИДРОКСАМОВЫЕ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ TNFα |
CA2319173A1 (en) | 1998-02-11 | 1999-08-19 | Jingwu Duan | Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US8030343B2 (en) | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
PT2087908T (pt) | 2001-06-26 | 2018-07-16 | Amgen Inc | Anticorpos contra opgl |
US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
WO2003086373A1 (en) | 2002-04-12 | 2003-10-23 | Celgene Corporation | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
EP2258363A1 (de) | 2002-05-17 | 2010-12-08 | Celgene Corporation | Zusammensetzungen zur Behandlung von Krebs |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
ZA200503024B (en) * | 2002-10-15 | 2006-11-29 | Celgene Corp | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
KR20050062649A (ko) * | 2002-10-31 | 2005-06-23 | 셀진 코포레이션 | 황반 변성의 치료 및 관리를 위한 선택적 시토킨 억제약물의 사용 방법 및 이를 포함하는 조성물 |
US7776907B2 (en) | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
CA2505131A1 (en) * | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
JP2006507324A (ja) * | 2002-11-06 | 2006-03-02 | セルジーン・コーポレーション | 骨髄増殖性疾患を治療および管理するための選択的サイトカイン阻害薬を含む組成物およびその使用法 |
CA2506442A1 (en) * | 2002-11-18 | 2004-07-01 | Celgene Corporation | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
AU2003294311B8 (en) * | 2002-11-18 | 2008-06-05 | Celgene Corporation | Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
ES2333220T3 (es) | 2002-12-30 | 2010-02-18 | Celgene Corporation | Compuestos 1,3-dihidro-isoindolilo sustituidos con fluoroalcoxi y sus usos farmaceuticos. |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
EP1605935A4 (de) * | 2003-03-06 | 2009-05-20 | Celgene Corp | Verfahren zur verwendung von und zusammensetzungen mit selektiven zyotkin-hemmenden arzneimitteln zur behandlung und versorgung von erkrankungen des zentralen nervensystems |
CN100427465C (zh) * | 2003-03-12 | 2008-10-22 | 细胞基因公司 | N-烷基-异羟肟酸-异吲哚基化合物及其药物用途 |
DE602004032522D1 (de) * | 2003-03-12 | 2011-06-16 | Celgene Corp | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung |
AU2004220457A1 (en) * | 2003-03-12 | 2004-09-23 | Celgene Corporation | 7-amino- isoindolyl compounds amd their pharmaceutical uses |
US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
DE10340739A1 (de) * | 2003-09-04 | 2005-04-07 | Satia Gmbh | Verfahren zur enzymatischen Herstellung von Mono- und Diacylglycerid-haltigen Emulgatoren |
CA2543132A1 (en) * | 2003-10-23 | 2005-05-19 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
WO2005110085A2 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
ZA200609228B (en) * | 2004-04-23 | 2008-05-28 | Celgene Corp | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension |
MXPA06012698A (es) * | 2004-05-05 | 2007-02-14 | Celgene Corp | Metodos y composiciones que utilizan farmacos inhibidores de citocina selectiva para el tratamiento y manejo de canceres y otras enfermedades. |
EP1746989A4 (de) * | 2004-05-05 | 2009-07-29 | Celgene Corp | Verfahren zur anwendung von selektiven cytokinhemmenden arzneimitteln zur behandlung und betreuung von myeloproliferativen krankheiten und zusammensetzungen, die diese arzneimittel enthalten |
US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
KR20070085454A (ko) * | 2004-10-28 | 2007-08-27 | 셀진 코포레이션 | 중추신경계 손상의 치료 및 관리를 위하여 pde4조절제를 사용하는 방법 및 조성물 |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
KR20090040352A (ko) | 2006-07-31 | 2009-04-23 | 얀센 파마슈티카 엔.브이. | 유로텐신 ⅱ 수용체 길항제 |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
PA8782701A1 (es) * | 2007-06-07 | 2009-01-23 | Janssen Pharmaceutica Nv | Antagonistas del receptor de urotensina ii |
DE602008004794D1 (de) | 2007-09-14 | 2011-03-10 | Addex Pharmaceuticals Sa | 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyridinyl-2'-one |
WO2010017105A1 (en) * | 2008-08-02 | 2010-02-11 | Janssen Pharmaceutica N.V. | Urotensin ii receptor antagonists |
BRPI0918055A2 (pt) | 2008-09-02 | 2015-12-01 | Addex Pharmaceuticals Sa | derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato. |
CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
EP2818164A1 (de) | 2009-02-10 | 2014-12-31 | Celgene Corporation | Verfahren zur Verwendung von und Zusammensetzungen mit PDE4-Modulatoren zur Behandlung, Vorbeugung und Handhabung von Tuberkulose |
DK2430022T3 (da) | 2009-05-12 | 2013-12-02 | Janssen Pharmaceuticals Inc | 1,2,4-Triazolo[4,3-a]pyridinderivater og deres anvendelse til behandlingen eller forebyggelse af neurologiske og psykiatriske lidelser |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
ES2409006T3 (es) | 2009-05-12 | 2013-06-24 | Janssen Pharmaceuticals Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de los receptores mGluR2 |
MX341050B (es) | 2010-04-07 | 2016-08-05 | Celgene Corp * | Metodos para tratar infeccion viral respiratoria. |
EP2583098B1 (de) | 2010-06-15 | 2018-08-08 | Celgene Corporation | Biomarker zur behandlung von schuppenflechte |
ES2552879T3 (es) | 2010-11-08 | 2015-12-02 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
AU2011328194B2 (en) | 2010-11-08 | 2015-04-16 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
JP5852665B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
CN102976974B (zh) * | 2012-12-29 | 2015-01-21 | 吉首大学 | 苯基苄基丙酰-n-甲基氧肟酸类尿素酶抑制剂及其合成和用途 |
CN102993152B (zh) * | 2012-12-29 | 2015-04-01 | 吉首大学 | 尿素酶抑制剂异黄酮氧肟酸化合物及其合成和用途 |
CN102993153B (zh) * | 2012-12-29 | 2015-05-13 | 吉首大学 | 异黄酮-n-甲基氧肟酸类尿素酶抑制剂及其合成和用途 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
KR20220039824A (ko) | 2014-01-21 | 2022-03-29 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
DK3096790T3 (da) | 2014-01-21 | 2019-10-07 | Janssen Pharmaceutica Nv | Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse |
EP3142663A1 (de) | 2014-05-16 | 2017-03-22 | Celgene Corporation | Zusammensetzungen und verfahren zur behandlung von arteriosklerotischen herz-kreislauf-erkrankungen mit pde4-modulatoren |
EP3157520B1 (de) | 2014-06-23 | 2019-09-04 | Celgene Corporation | Apremilast zur behandlung einer lebererkrankung oder leberfunktionsanomalie |
WO2017030892A1 (en) | 2015-08-14 | 2017-02-23 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
KR102445637B1 (ko) * | 2017-11-28 | 2022-09-22 | 솔브레인 주식회사 | 레벨링제 및 이를 포함하는 전기도금 조성물 |
CA3094029A1 (en) * | 2018-04-17 | 2019-10-24 | Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd | Isoindole derivatives and their use as immunoglobulin modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4077998A (en) * | 1975-10-28 | 1978-03-07 | Morton-Norwich Products, Inc. | Phthaloyl amino acid hydroxamic acids |
US4173652A (en) | 1976-12-18 | 1979-11-06 | Akzona Incorporated | Pharmaceutical hydroxamic acid compositions and uses thereof |
US4820828A (en) | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
CA2227237C (en) | 1995-07-26 | 2005-12-13 | Pfizer Inc. | N-(aroyl)glycine hydroxamic acid derivatives and related compounds |
RU2199530C2 (ru) * | 1997-07-31 | 2003-02-27 | Селджин Корпорейшн | ЗАМЕЩЕННЫЕ ГИДРОКСАМОВЫЕ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ TNFα |
-
1998
- 1998-07-30 RU RU2000102639/04A patent/RU2199530C2/ru not_active IP Right Cessation
- 1998-07-30 CZ CZ20000256A patent/CZ299873B6/cs not_active IP Right Cessation
- 1998-07-30 PT PT98938151T patent/PT1035848E/pt unknown
- 1998-07-30 CA CA002295295A patent/CA2295295A1/en not_active Abandoned
- 1998-07-30 HU HU0003761A patent/HUP0003761A3/hu unknown
- 1998-07-30 AT AT98938151T patent/ATE238052T1/de not_active IP Right Cessation
- 1998-07-30 NZ NZ502379A patent/NZ502379A/xx unknown
- 1998-07-30 BR BR9815895-3A patent/BR9815895A/pt not_active Application Discontinuation
- 1998-07-30 CN CN98807775A patent/CN1265590A/zh active Pending
- 1998-07-30 AU AU86741/98A patent/AU737008B2/en not_active Ceased
- 1998-07-30 ES ES98938151T patent/ES2196592T3/es not_active Expired - Lifetime
- 1998-07-30 JP JP2000504855A patent/JP2001511448A/ja active Pending
- 1998-07-30 KR KR1020007001011A patent/KR100716475B1/ko not_active IP Right Cessation
- 1998-07-30 EP EP98938151A patent/EP1035848B1/de not_active Expired - Lifetime
- 1998-07-30 US US09/126,157 patent/US6214857B1/en not_active Expired - Fee Related
- 1998-07-30 DE DE69813876T patent/DE69813876T2/de not_active Expired - Fee Related
- 1998-07-30 WO PCT/US1998/015868 patent/WO1999006041A1/en active IP Right Grant
- 1998-07-30 TR TR2000/00221T patent/TR200000221T2/xx unknown
-
1999
- 1999-12-28 NO NO19996529A patent/NO315043B1/no not_active IP Right Cessation
-
2000
- 2000-01-12 FI FI20000061A patent/FI119841B/fi active IP Right Grant
-
2001
- 2001-02-09 US US09/780,725 patent/US6656964B2/en not_active Expired - Fee Related
-
2003
- 2003-06-16 US US10/462,319 patent/US7091356B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1035848B1 (de) | 2003-04-23 |
DE69813876D1 (de) | 2003-05-28 |
DE69813876T2 (de) | 2004-01-29 |
CA2295295A1 (en) | 1999-02-11 |
EP1035848A1 (de) | 2000-09-20 |
PT1035848E (pt) | 2003-09-30 |
AU737008B2 (en) | 2001-08-09 |
KR100716475B1 (ko) | 2007-05-10 |
AU8674198A (en) | 1999-02-22 |
NZ502379A (en) | 2002-10-25 |
RU2199530C2 (ru) | 2003-02-27 |
US6214857B1 (en) | 2001-04-10 |
EP1035848A4 (de) | 2001-05-23 |
FI119841B (fi) | 2009-04-15 |
CZ299873B6 (cs) | 2008-12-17 |
HUP0003761A3 (en) | 2001-04-28 |
NO315043B1 (no) | 2003-06-30 |
NO996529D0 (no) | 1999-12-28 |
US6656964B2 (en) | 2003-12-02 |
FI20000061A (fi) | 2000-03-02 |
US20010049371A1 (en) | 2001-12-06 |
BR9815895A (pt) | 2001-01-16 |
US20040006096A1 (en) | 2004-01-08 |
US7091356B2 (en) | 2006-08-15 |
CZ2000256A3 (cs) | 2000-06-14 |
TR200000221T2 (tr) | 2000-09-21 |
NO996529L (no) | 2000-03-28 |
KR20010022429A (ko) | 2001-03-15 |
HUP0003761A2 (en) | 2001-03-28 |
ES2196592T3 (es) | 2003-12-16 |
WO1999006041A1 (en) | 1999-02-11 |
CN1265590A (zh) | 2000-09-06 |
JP2001511448A (ja) | 2001-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE238052T1 (de) | Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels | |
PT1038039E (pt) | Inoculante de ferro fundido e metedo para producao do inoculante de ferro fundido | |
DE69739629D1 (de) | Vorrichtung zur erhohung der sehkraft und zur verbesserten auflosung von fundusaufnahmen | |
DE69936873D1 (de) | Verfahren und System zur Vemittlung von Sitzungen und Anrufen | |
DE69835020D1 (de) | Plasmabrenner und verwendungsverfahren dieses plasmabrenners | |
DE69730473D1 (de) | System zur Kodierung und Übertragung von Sprachsignalen | |
DE60128677D1 (de) | Verfahren und vorrichtung zur prädiktiven quantisierung von stimmhaften sprachsignalen | |
ID19293A (id) | Proses pembuatan dan penggunaan aditif semen | |
DE59808633D1 (de) | Verfahren zur aktiven dämpfung einer verbrennungsschwingung und anwendung des verfarens | |
DE19780309D2 (de) | Verfahren zur Regelung eines Aggregats und Frequenzumrichter | |
DE69630331D1 (de) | Verfahren zur gesicherten Sitzungsschlüsselerzeugung und zur Authentifizierung | |
NO940819L (no) | Inokuleringsmiddel for stöpejern og fremgangsmåte for fremstilling av inokuleringsmiddel | |
ID26400A (id) | Alat dan metode pengoreksi kesalahan bentuk luar | |
DE69733137D1 (de) | Inhibitoren von picornavirus 3c protease und verfahren zur herstellung und verwendung | |
ID19459A (id) | Metoda dan peralatn penyampaian pesan | |
DE69714862T2 (de) | Lösungen und verfahren zur oberblächenbehandlung von metallen | |
ID22650A (id) | Penggunaan penghambat-penghambat lipase usus lambung | |
DE59509471D1 (de) | Verfahren zur regelung des lastannahme- und beschleunigungsverhaltens von aufgeladenen brennkraftmaschinen | |
DE19726292B8 (de) | Verfahren zur geräuschlosen Überwachung von Telefongesprächen | |
DE69813022D1 (de) | Injektor zur behandlung von metallschmelzen mit gasen | |
DE69828735D1 (de) | Vorrichtung und System zur Stimmwiedergabe | |
DE59709922D1 (de) | Pflaster zur transdermalen anwendung von pergolid | |
DE19681411D2 (de) | Verfahren zur Verringerung des Innenwiderstandes von wiederaufladbaren Akkumulatoren | |
DE69714666D1 (de) | Benzothiophen-Verbindungen und Verfahren zur Anwendung | |
DE19680627D2 (de) | Lichtbogenofen, insbesondere Gleichstromlichtbogenofen und Verfahren zur Vermeidung von Überhitzungen der Ofenwand |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1035848 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |